header logo image


Page 231«..1020..230231232233..240250..»

Combined forces help combat the pain and disability of arthritis – Western News

January 19th, 2021 12:48 pm

Getting dressed, brushing teeth, opening a jar to make a meal: many Canadians can take performing these tasks for granted. But for those living with osteoarthritis in their hands, the gripping and twisting motions of daily life are a regular source of pain and frustration.

It can affect everything. Living with pain certainly has an impact, but it extends to all dimensions of life, said Joy MacDermid, professor of physical therapy and co-director of the clinical research lab at the Roth | McFarlane Hand and Upper Limb Centre.

There are also economic implications if work is affected, as well as increased risk for isolation and depression. We often hear from people whove had to give up things they value, like participating in sports, or doing crafts they used to enjoy, said MacDermid. Those activities are related to their social life and often done with friends.

Joy MacDermid, PhD

She and her colleagues are working on improving the quality of life for those living with hand osteoarthritis by studying the force used in daily tasks to develop new joint protection programs. Her research, done with the assistance of Pavlos Bobos, PhD20, and in collaboration with engineering professors Louis Ferreira and Emily Lalone through Westerns Bone and Joint Institute, has received recognition from the Arthritis Society as one of its Top 10 Research Advances of 2020.

Pavlos Bobos, PhD

Louis Ferreira, PhD

Emily Lalone, PhD

Joint protection programs a group of strategies to decrease strain on the joints have included training patients to do tasks differently, to use assistive devices or to pace high-force activities like carrying a heavy laundry basket throughout the day.

Until now, these programs have been based on theory alone, MacDermid said. Weve always thought if you put your joint in a neutral position, it makes sense biomechanically that it would lessen force through the joints, but we didnt have measurements demonstrating that joint protection worked. We needed devices to do that.

Thats where Ferreiras and Lalones expertise in mechanical and material engineering, and specifically wearable technology, comes in. Ferreira designed a sensor allowing Lalone and her graduate students to measure, in real time, the forces in fingertips when performing functional tasks. Tiny strain gauges attached to the nailbed pick up a recording when the finger is depressed.

Sensors embedded in finger sleeves measured the force of daily tasks.

The first design saw the sensor embedded in fake fingernails, then evolved through the teams investigations to be worn in small finger sleeves by test subjects in MacDermids lab.

We had a kitchen area set up and a series of standardized tasks that patients would go through, such as pouring a tea kettle or lifting a cup, she said. Patients were tested, first doing tasks their own way, then repeating them using joint protection strategies. The subjects were videotaped, and data on the amount of movement and force used for each task was analyzed.

Early results showed some strategies are very effective in reducing the amount of force going through the joint, but there were also unexpected observations. There seems to be some tasks that people naturally gravitate toward doing correctly, MacDermid said. For example, patients knew inherently how to lift a kettle in the best way to avoid strain. But with other tasks they had no idea when they were doing it incorrectly.

Biofeedback, in the form of an audio or visual cue while doing a task, could help patients avoid joint strain in the future, the study found.

This is part of MacDermids long-term vision, made possible through the transdisciplinary effort fostered through the Bone and Joint Institute.

We first want to create an intervention where people would wear the sensors in the clinic and get feedback, she said. But in the long-term, as sensor technology develops and becomes more stable, were hoping we can give people a kit that gives them feedback when they practise the tasks in their own home for two or three weeks.

Shes hoping her work will also influence updates to patient training materials, noting some still suggest using a pencil rather than a finger to dial a rotary phone. The tasks people do today and the types of assistive devices we have to help people now are so different.

The rest is here:
Combined forces help combat the pain and disability of arthritis - Western News

Read More...

Effect of mannose-binding lectin gene polymorphisms on the risk of rheumatoid arthritis: Evidence from a meta-analysis – DocWire News

January 19th, 2021 12:48 pm

Background:The effect of mannose-binding lectin (MBL) gene polymorphisms on susceptibility of rheumatoid arthritis (RA) were evaluated in ethnically different populations, whereas the results were always inconsistent.

Materials and methods:Fourteen articles involving 36 datasets were recruited to evaluate the association between MBL gene polymorphisms and rheumatoid arthritis in a meta-analysis. The random or fixed effect models were used to evaluate the pooled odds ratios (ORs) and their corresponding 95% confidence intervals (CIs).

Results:Stratified analysis by ethnicities was conducted and the result revealed that rs1800450 (T vs C, OR = 1.32, 95% CI: 1.04-1.67, P < .05) and MBL-A/O (T vs C, OR = 1.20, 95% CI: 1.08-1.34, P < .001) were strongly associated with RA in Brazilian populations. In addition, the significant relationship between rs11003125 (T vs C, OR = 1.16, 95% CI: 1.06-1.26, P < .05) with RA were also observed in East Asian populations. Meanwhile, the inverse associations between rs5030737 with RA in East Asians and rs1800450 with RA in Indians were acquired. However, no association between any MBL polymorphism with RA susceptibility was confirmed in Caucasians.

Conclusions:The structural polymorphisms in exon 1 of MBL gene may significantly contribute to susceptibility and development of RA in Brazilian and Indian populations, whereas the functional polymorphisms in the promoter region were more likely to associate with RA in East Asians.

Keywords:mannose-binding lectin; meta-analysis; polymorphism; rheumatoid arthritis.

Go here to see the original:
Effect of mannose-binding lectin gene polymorphisms on the risk of rheumatoid arthritis: Evidence from a meta-analysis - DocWire News

Read More...

Social stressors and risk of rheumatoid arthritis and their relationship to known modifiable risk factors: results from the Swedish EIRA study -…

January 19th, 2021 12:48 pm

Objectives: To investigate whether low social support or low decision latitude at work correlate with risk of rheumatoid arthritis (RA), and whether and how those factors are associated with known modifiable risk factors for RA.

Method: The Swedish population-based EIRA study included, from 1996 to 2015, 3724 incident RA cases and 5935 controls, matched for age, gender, and residential area. Participants filled in detailed questionnaires at diagnosis. Using logistic regression, we investigated whether low social support and low decision latitude at work were associated with RA risk, and whether and how these exposures are associated with known modifiable risk factors for RA.

Results: Low decision latitude at work was associated with RA risk in unadjusted analyses [odd ratio (OR) = 1.52, 95% confidence interval (CI) = 1.20-1.94], but this association was weakened after adjustment for known RA risk factors (adjusted OR = 1.24, 95% CI = 0.93-1.63). Low social support was not associated with RA risk (unadjusted OR = 1.05, 95% CI = 0.95-1.15). Cases reporting low decision latitude were more often smokers (OR = 2.05, 95% CI = 1.33-3.16), without university degrees (OR = 8.23, 95% CI = 5.13-13.22), and more often female (OR = 2.52, 95% CI = 1.66-3.81), with a similar pattern among controls. Cases reporting low social support were more often men (OR = 1.60, 95% CI = 1.40-1.83), smokers (OR = 1.46, 95% CI = 1.26-1.70), obese (OR = 1.29, 95% CI = 1.09-1.54), physically inactive (OR = 2.78, 95% CI = 1.98-3.90), and without university degrees (OR = 2.04, 95% CI = 1.77-2.36), with a similar pattern among controls.

Conclusion: Low decision latitude coexisted with several known environmental/social risk factors for RA, together defining groups of individuals at increased risk of RA. These risk factors should be viewed in context when testing actions to diminish RA risk in prospective studies.

Visit link:
Social stressors and risk of rheumatoid arthritis and their relationship to known modifiable risk factors: results from the Swedish EIRA study -...

Read More...

Arterial wall inflammation is increased in rheumatoid arthritis compared with osteoarthritis, as a marker of early atherosclerosis – DocWire News

January 19th, 2021 12:48 pm

Objective:RA is associated with higher risk of cardiovascular (CV) disease. Ongoing systemic inflammation is presumed to accelerate atherosclerosis by increasing inflammation in the arterial wall. However, evidence supporting this hypothesis is limited. We aimed to investigate arterial wall inflammation in RA vs OA, and its association with markers of inflammation and CV risk factors.

Methods:18-fluorodeoxyglucose PET combined with CT (18F-FDG-PET/CT) was performed in RA (n = 61) and OA (n = 28) to investigate inflammatory activity in the wall of large arteries. Secondary analyses were performed in patients with early untreated RA (n = 30), and established RA, active under DMARD treatment (n = 31) vs OA.

Results:Patients with RA had significantly higher 18F-FDG uptake in the wall of the carotid arteries (beta 0.27, 95%CI 0.11-0.44, P <0.01) and the aorta (beta 0.47, 95%CI 0.17-0.76, P <0.01) when compared with OA, which persisted after adjustment for traditional CV risk factors. Patients with early RA had the highest 18F-FDG uptake, followed by patients with established RA and OA respectively. Higher ESR and DAS of 28 joints values were associated with higher 18F-FDG uptake in all arterial segments.

Conclusion:Patients with RA have increased 18F-FDG uptake in the arterial wall compared with patients with OA, as a possible marker of early atherosclerosis. Furthermore, a higher level of clinical disease activity and circulating inflammatory markers was associated with higher arterial 18F-FDG uptake, which may support a role of arterial wall inflammation in the pathogenesis of vascular complications in patients with RA.

Keywords:FDG PET/CT; RA; atherosclerosis; inflammation.

Read the rest here:
Arterial wall inflammation is increased in rheumatoid arthritis compared with osteoarthritis, as a marker of early atherosclerosis - DocWire News

Read More...

Versus Arthritis appoints new director of research – Charity Today News

January 19th, 2021 12:48 pm

VERSUS Arthritis, the UKs leading charity for people with arthritis, has appointed Dr Neha Issar-Brown as its new Director of Research.

Neha joins from Fight for Sight where she was Director of Research, Policy and Innovation, supporting pioneering research to prevent sight loss. She also initiated the framework for the charitys first patient-centred research strategy.

In her new role, Neha will be responsible for developing Versus Arthritis own research strategy, aimed at making sure that research discoveries are rapidly translated into life-changing treatments for people with arthritis, along with ensuring that the level of investment in arthritis research reflects the prevalence of a condition that impacts one in six people in the UK.

Her previous roles include Head of Population Health and System Medicine at the UKRIs Medical Research Council (MRC).

Neha will be taking up her new position in February and said:

I am thrilled to be joining Versus Arthritis at this exciting time in the development of its research strategy.

I am particularly excited about working for an organisation that has such a strong track record in putting people with arthritis at the heart of its work, ensuring that no decision is made without the involvement of those who will be directly impacted.

Im looking forward to becoming part of an amazing team and to driving progress for millions of people with arthritis.

Ellen Miller, Deputy Chief Executive of Versus Arthritis, said:

Were delighted to welcome Neha to Versus Arthritis at such a significant time.

The COVID-19 pandemic and Brexit have put a huge strain on medical research charities, but with Nehas breadth of experience alongside our incredible partners and supporters, were in a very good position to build on and continue supporting world-leading research that will fundamentally change the lives of people with arthritis.

See the article here:
Versus Arthritis appoints new director of research - Charity Today News

Read More...

Global Rheumatoid Arthritis (RA) Market Analysis & Drug Forecasts, 2019-2020 & 2029 – Biosimilar and Generic Erosion Will Stymie Sales Growth…

January 19th, 2021 12:48 pm

DUBLIN--(BUSINESS WIRE)--The "Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2029" report has been added to ResearchAndMarkets.com's offering.

Global revenues from RA drug sales are expected to grow from $26.2B in 2019 to $29.1B in 2029.

The publisher projects that the global RA marketplace - which, for the purposes of this report, comprises eight major pharmaceutical markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Australia) - will grow at a compound annual growth rate (CAGR) of 1.0% over the 10-year forecast.

Global growth in the RA market will be driven by continued uptake of new products in the IL-6 and JAK inhibitor classes along with the anticipated approval and launch of four pipeline therapies. This growth will be slackened by sales erosion from biosimilars and generic tofacitinib. Over 70% of sales will come from the US; the US has a large population of RA patients (estimated 1.8M diagnosed prevalent cases in 2029) and high price tags for biologic and targeted synthetic disease modifying anti-rheumatic drugs (DMARDs).

Biosimilar erosion will temper the growth of the RA market during the forecast period; between 2019 and 2029, biosimilars sales will increase from 5% to 28% of global sales. Due to favorable local regulations and increased access, biosimilar uptake is expected to be the highest in the 5EU; by 2029, the publisher projects that biosimilar sales in 5EU will represent over 45% of its total sales -60% of which will come from sales of adalimumab and etanercept biosimilars.

The publisher expects that despite biosimilar erosion, Pfizer/Amgen's Enbrel and AbbVie's Humira will remain the global sales leaders during the forecast period, amassing combined sales of $12.6B in 2019 and $9.0B in 2029. Sales of Enbrel and Humira are more likely to be protected from biosimilar erosion than Remicade (negative CAGR of 6.8%) mainly due to a lack of biosimilar availability in the US, the largest RA market in the 8MM. Etanercept and adalimumab biosimilars will not be available in the US until 2028 and 2023, respectively.

Although biosimilars may temper the impact of blockbuster biologics, the publisher expects that the growth of the small molecule Janus kinase (JAK) inhibitor class will powerfully shape the RA market of the future. The publisher projects that the JAK inhibitor class will continue to grow significantly over the forecast period, increasing at a CAGR of 7.2%. This growth is expected to be strongest in the 5EU, where the first JAK inhibitors, Pfizer's Xeljanz and Eli Lilly's Olumiant, only became available starting in 2017. The recent global launch of AbbVie's JAK1 inhibitor, Rinvoq, is expected to significantly expand JAK inhibitor market share, bringing in $2.2B in sales by 2029.

The late-stage pipeline for RA consists of three subcutaneously delivered biologics (the TNF inhibitor ozoralizumab, the interleukin 6 [IL-6] inhibitor olokizumab, and the granulocyte-macrophage colony-stimulating factor [GM-CSF] inhibitor otilimab) and one oral kinase inhibitor (the BTK inhibitor fenebrutinib). Key opinion leaders (KOLs) expressed measured enthusiasm for these agents-they welcomed the potential availability of new mechanisms of action but did not think that any of them would be more or even equally effective as JAK inhibitors.

Of these agents, KOLs were the most enthusiastic about GSK's GM-CSF inhibitor, otilimab, expected to achieve global sales of $626.8M by 2029. All together, these four pipeline agents are expected to claim less than 5% of the RA market in 2029, equivalent to about $1.1B.

Key Topics Covered:

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Rheumatoid Arthritis: Executive Summary

2.1 Biosimilar and Generic Erosion Will Stymie Sales Growth in the RA Market from 2019-2029

2.2 Development of Novel Oral Agents and Biosimilars Are Popular R&D Strategies

2.3 Opportunities Remain for More Rapid, Targeted, and Cost-Effective Treatment for RA Patients

2.4 Late-Stage RA Pipeline Holds Promise But Likely Won't Match the Utility of JAK Inhibitors

2.5 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology

4.2 Pathophysiology

4.3 Symptoms and Severity Classifications

5 Epidemiology

5.1 Risk Factors and Comorbidities

5.2 Global and Historical Trends

5.3 Forecast Methodology

5.4 Epidemiological Forecast for RA (2019-2029)

5.5 Discussion

6 Disease Management

6.1 Diagnosis and Treatment Overview

6.2 US

6.3 5EU

6.4 Japan

6.5 Australia

7 Competitive Assessment

7.1 Overview

7.2 Biosimilars in the RA Market

8 Unmet Needs and Opportunity Assessment

8.1 Overview

8.2 Earlier Diagnosis and Treatment

8.3 Cost-Effective Therapies

8.4 Personalized Treatment Strategies

8.5 Improved Guidance on Treating RA Patients in Remission

8.6 New Treatment Options for Patients with Refractory RA

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

9.3 Other Drugs in Development - Kinase Inhibitors

10. Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

10.3 Company Portfolio Assessments

11. Market Outlook

11.1 Global Markets

11.2 US

11.3 5EU

11.4 Japan

11.5 Australia

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/ba8mff

Read the original here:
Global Rheumatoid Arthritis (RA) Market Analysis & Drug Forecasts, 2019-2020 & 2029 - Biosimilar and Generic Erosion Will Stymie Sales Growth...

Read More...

Mary Berry explains ‘funny’ left hand and health battle: ‘Everybody thinks it’s arthritis’ – Express

January 19th, 2021 12:48 pm

Mary Berry, 85, is very hands on when it comes to baking, with numerous cooking shows and books behind her that fans wonder if there's anything those hands of hers can't do! But the pastry whizz admitted she suffers with a "funny left hand"; the aftermath of suffering with polio when she was younger.

Polio is a serious viral infection that used to be common in the UK and worldwide, which can infect a person's spinal cord, causing paralysis of the limbs.

At the age of 13, Marycontracted the disease and spent three months in hospital in isolation.

The condition only affected the left side of her body, affecting her hand which isoften mistaken forarthritisby television viewers.

Regardless, she admitted she was "let off very lightly" under the circumstances.

READ MORE:Bake Off star Dave Friday's fiance diagnosed with sepsis

In a recent interview, the 85-year-old spoke about her diagnosis and how she would urge everyone to take the vaccine to protect themselves against the relentless disease.

"I had polio, but now almost the whole world is vaccinated against it," she said.

"If youre in a hospital like I was, with people in callipers, people in pain, people who werent going to get better I think everyone should take the vaccine, not query it, and think of others."

She added: "I was immensely fortunate. I only had it on my left side, and Ive got a funny left hand.

"Everybody thinks Ive got arthritis. I look a bit funny when Im rolling pastry, but I have no other difficulties whatsoever."

She confessed she wasn't as good as sport as she used to be prior to the illness but remains "grateful".

"I was let off very lightly. Im grateful," she told Radio Times.

Her previous health battle comes after Mary and her husband both received the coronavirus vaccine earlier this month, as the UK government continue to roll the Pfizer vaccine, which has currently reached over four million people.

Much like her appreciation for vaccines for viral diseases such as polio, Mary was adamant no one should turn this down.

DON'T MISS...Ralf Little embroiled in row with Death In Paradise director on-setHomes Under The Hammer's Martin Roberts attacks 2020 sign with hammerCountdown's Susie Dent tried to persuade Joe Lycett to 'get willy out'

She said: "I was so pleased, particularly for my husband.

"I would encourage everyone, if its offered to them, to definitely have the vaccine."

Like the rest if us, she has been separated from her family members for far too long, unable to see much of her five grandchildren during lockdown but she explained they have kept in touch by phone.

"I think that were very lucky in this day and age to have all these different forms of communication," Mary admitted.

She continued to joke: "And because Im quite ancient, Ive got a lot of girlfriends whove lost their husbands or their other halves. Its been great having phone calls with them. What are they getting up to? How are they coping?"

She explained she makes sure she rings someone every day to have a "long, long chat", something she never would have found the time to do before.

Mary's full interview is available to read now in Radio Times.

Link:
Mary Berry explains 'funny' left hand and health battle: 'Everybody thinks it's arthritis' - Express

Read More...

Having a co-morbidity predicts worse outcome in early rheumatoid arthritis despite intensive treatment: a post hoc evaluation of the pragmatic…

January 19th, 2021 12:48 pm

Objectives:To quantify the prevalence of co-morbidities in patients with early RA and determine their prognostic value for effectiveness outcomes in a randomized trial.

Methods:We included patients from the 2-year pragmatic randomized CareRA trial, who had early RA (diagnosis < 1 year), were DMARD nave and then treated-to-target with different remission induction schemes. Prevalence of co-morbidities was registered at baseline and the Rheumatic Diseases Comorbidity Index (RDCI; range 0-9) was calculated. We tested the relation between baseline RDCI and outcomes including disease activity (DAS28-CRP), physical function (HAQ index), quality of life (SF-36 domains) and hospitalizations over 2 years, using linear mixed models or generalized estimating equations models.

Results:Of 379 included patients, 167 (44%) had a RDCI of minimum 1. RDCI scores of 1, 2 or 3 were obtained in 65 (17%), 70 (19%), and 32 (8%) participants, respectively. The most frequent co-morbidity was hypertension (22%). Patients with co-morbidities had significantly higher HAQ ( = 0.215; 95% CI: 0.071, 0.358), DAS28-CRP ( = 0.225; 95% CI: 0.132, 0.319) and lower SF-36 physical component summary scores ( =-3.195; 95% CI: -4.844, -1.546) over 2 years than patients without co-morbidities, after adjusting for possible confounders including disease activity and randomized treatment. Patients with co-morbidities had over time lower chances of achieving remission (OR = 0.724; 95% CI: 0.604, 0.867) and a higher risk of hospitalization (OR = 3.725; 95% CI: 2.136, 6.494).

Conclusion:At disease onset, almost half of RA patients had at least one clinically important co-morbidity. Having co-morbidities was associated with worse functionality and disease activity outcomes over 2 years, despite intensive remission induction treatment.

Trial registration:Clinical trialsNCT01172639.

Keywords:co-morbidities; csDMARDs; disease activity; functionality; glucocorticoids; rheumatoid arthritis; treatment strategies.

See original here:
Having a co-morbidity predicts worse outcome in early rheumatoid arthritis despite intensive treatment: a post hoc evaluation of the pragmatic...

Read More...

Arthritis patient cannot see how surgery waiting lists will be fixed – Aberdeen Evening Express

January 19th, 2021 12:48 pm

A man living in permanent pain and left virtually housebound by arthritis who had his hip operation cancelled due to the pandemic has said he cannot see how the mounting NHS waiting list backlog will be sorted.

Chris Bulteel was diagnosed with arthritis in his right hip in 2018 and was due to have a hip replacement in March 2020 but the operation was cancelled due to the coronavirus outbreak.

He told the PA news agency that although he had been told he would be top of the list for another operation he said he was later taken off the waiting list and does not know when he will receive the vital surgery.

The 71-year-old from Dorset added: While I have got a supportive family who make my life a lot easier I couldnt cope on my own I worry about all those people who are on their own.

They must be really suffering, its a terrible situation and I cant see how they ever get this waiting list back to normal.

I am in permanent pain, its quite severe at times.

Its there all the time in the background. I have to have a chair that lifts me up in the air, it really is a struggle to get around on two crutches.

Its getting gradually worse and I can see a time coming up when I wont be able to walk at all.

Mr Bulteel, who said he is supported by his wife Angela and his daughter Sarah and her partner, said that he understood the need to cancel surgery due to the pandemic.

But he said he just wanted to know when he could have the operation.

The former care worker added: I appreciate they are not doing anything at the moment because of the pandemic but it would be nice to know what the situation is because of the waiting lists.

I used to be on the top but now Im not on it at all.

Mr Bulteel said he has only left his flat twice since March for hospital appointments, cannot shower unaided or get down the steps to his garden and is on medication for the pain.

He also said he worries he will not be able to get the coronavirus vaccine because he wont be able to get to a vaccination centre.

Mr Bulteel added: I havent been out since March, except for two visits to the hospital.

I am lucky I live in a ground floor flat and have a garden to look out into but I cant even get out because theres a step I cant negotiate.

Im also worried I cant have the vaccine when the time comes because I cant get to any vaccination centre.

Mr Bulteel said he had taken up writing but he now cannot sit at his computer for more than 10 minutes.

He said that after the operation he wants to write again as well as hopefully go back and do some care work again.

He said the operation would mean an awful lot to him and his family and added: I know Im not a burden but you feel you are.

Tracey Loftis, head of policy and public affairs at the charity Versus Arthritis said delays to treatment can lead to serious physical and mental health implications.

She added: Delays to planned treatment can lead to serious physical and mental health implications, especially for those with arthritis who have debilitating pain or limited mobility.

Whilst it is understandable that operations are cancelled at this time, thousands of people are having to endure longer periods of pain.

People waiting for joint replacement surgery urgently need clear communication about their care, and support including advice on pain management and mental health and wellbeing.

Read more:
Arthritis patient cannot see how surgery waiting lists will be fixed - Aberdeen Evening Express

Read More...

Prescription Arthritis Medications Market Size By Analysis, Key Vendors, Regions, Type and Application, and Forecasts to 2027 – NeighborWebSJ

January 19th, 2021 12:48 pm

Fort Collins, Colorado: Reports Globe has published the latest study on Prescription Arthritis Medications Market Report Analysis by Size with Future Outlook, Key Players SWOT Analysis and Forecast to 2026. It uses exploratory techniques such as qualitative and quantitative analysis to identify and present data on the target market. Successful sales strategies have been mentioned that will help you do business in record time and multiply customers.

This report is presented clearly and concisely to help you better understand the structure and dynamics of the market. The trends and recent developments in the Prescription Arthritis Medications market were analyzed. The opportunities that lead to the growth of the market were analyzed and presented. Focusing on the global market, the report provides answers to the key questions stakeholders are facing today around the world. Information on market size raises the problem of increasing competitiveness and hampering market-leading sectors and market growth.

Get Exclusive Sample of Report on Prescription Arthritis Medications market is available @ https://reportsglobe.com/download-sample/?rid=113490

Some of the Important and Key Players of the Global Prescription Arthritis Medications Market:

Prescription Arthritis Medications market research report provides detailed information on the following aspects: Industry Size, Market Share, Growth, Segmentation, Manufacturers and Advancement, Key Trends, Market Drivers, Challenges, Standardization, Deployment Models, Opportunities, Strategies, Future Roadmaps and Annual Forecasts to 2027, etc. The report will help you also in understanding the dynamic structure of the Prescription Arthritis Medications market by identifying and analyzing market segments. The Global Prescription Arthritis Medications 2021 Industry Research Report has given the expected compound annual growth rate (CAGR) as a% of value for a given period of time and clearly helps the user make their decision based on the futuristic chart of the key players on the global Prescription Arthritis Medications market. The report introduces some of the major players in the global Prescription Arthritis Medications market and offers insightful information about the Prescription Arthritis Medications industry such as Business Overview, Prescription Arthritis Medications Market Product Segmentation, Revenue Segmentation, and the Latest Information. Developments.

Additionally, the Prescription Arthritis Medications market report includes a comprehensive strategic review as well as summarized studies of the growth, key factors, and market opportunity by which to evaluate the Prescription Arthritis Medications market and other important market related details on Prescription Arthritis Medications. The investigation of the research report also helps uncover accurate industry statistics depicting the ultimate model of the global Prescription Arthritis Medications market, including various types, applications, market growth structures, and opportunities. In addition, the study of the market research report provides an investigation and analysis of the past and current performance of the regional market that includes regions by department and subdivision. This regional analysis studies various key market parameters such as Prescription Arthritis Medications market growth rate in each region, production volume and capacity, market demand and supply, and return on investment (RoI).

Request a Discount on the report @ https://reportsglobe.com/ask-for-discount/?rid=113490

Some of the key questions answered in the report include-

1. What is the overall structure of the market?2. What was the historical value and what is the forecasted value of the market?3. What are the key product level trends in the market?4. What are the market level trends in the market?5. Which of the market players are leading and what are their key differential strategies to retain their stronghold?6. Which are the most lucrative regions in the market space?

Browse the complete report @ https://reportsglobe.com/product/global-prescription-arthritis-medications-market-insight-and-forecast/

Global Prescription Arthritis Medications market is segmented based by type, application and region.

Prescription Arthritis Medications Market Segmentation, By Type

Prescription Arthritis Medications Market Segmentation, By Application

The prime objective of this report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing. Deep researches and analysis were done during the preparation of the report. The readers will find this report very helpful in understanding the market in depth. The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts. The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better.

Global Prescription Arthritis Medicationsmarket Key Report Highlights:

This in-depth research documentation offers an illustrative overview of the entire market outlook with details on scope, executive summary, and market segments The report also includes sections on the competitive spectrum, highlighting major players, with a detailed assessment of supply chain management, competition dynamics, and growth objectives. Other crucial details on Porters Five Forces assessment, SWOT analysis, and data triangulation methods have also been included in the report. Other relevant details on production patterns, growth rate, market share of each of the segments have also been pinned in the report. The report also houses crucial analytical details on revenue share and sales projections, besides volumetric estimations of each of the product segments have also been highlighted in the report to encourage unfaltering market decisions and sustainable revenue streams in the global Prescription Arthritis Medications market.A dedicated chapter on COVID-19 analysis has therefore been included in this versatile report to encourage future-ready business discretion aligning with post-COVID-19 market environment.

Major Points from Table of Content:

1. Executive Summary2. Assumptions and Acronyms Used3. Research Methodology4. Prescription Arthritis Medications Market Overview5. Prescription Arthritis Medications Supply Chain Analysis6. Prescription Arthritis Medications Pricing Analysis7. Global Prescription Arthritis Medications Market Analysis and Forecast by Type8. Global Prescription Arthritis Medications Market Analysis and Forecast by Application9. Global Prescription Arthritis Medications Market Analysis and Forecast by Sales Channel10. Global Prescription Arthritis Medications Market Analysis and Forecast by Region11. North America Prescription Arthritis Medications Market Analysis and Forecast12. Latin America Prescription Arthritis Medications Market Analysis and Forecast13. Europe Prescription Arthritis Medications Market Analysis and Forecast14. Asia Pacific Prescription Arthritis Medications Market Analysis and Forecast15. Middle East & Africa Prescription Arthritis Medications Market Analysis and Forecast16. Competition Landscape

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @ https://reportsglobe.com/need-customization/?rid=113490

How Reports Globe is different than other Market Research Providers:

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Contact us:

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email: [emailprotected]

Web: reportsglobe.com

Originally posted here:
Prescription Arthritis Medications Market Size By Analysis, Key Vendors, Regions, Type and Application, and Forecasts to 2027 - NeighborWebSJ

Read More...

Seropositive Rheumatoid Arthritis Drug Market Size By Analysis, Key Vendors, Regions, Type and Application, and Forecasts to 2027 – NeighborWebSJ

January 19th, 2021 12:48 pm

Fort Collins, Colorado: Reports Globe has published the latest study on Seropositive Rheumatoid Arthritis Drug Market Report Analysis by Size with Future Outlook, Key Players SWOT Analysis and Forecast to 2026. It uses exploratory techniques such as qualitative and quantitative analysis to identify and present data on the target market. Successful sales strategies have been mentioned that will help you do business in record time and multiply customers.

This report is presented clearly and concisely to help you better understand the structure and dynamics of the market. The trends and recent developments in the Seropositive Rheumatoid Arthritis Drug market were analyzed. The opportunities that lead to the growth of the market were analyzed and presented. Focusing on the global market, the report provides answers to the key questions stakeholders are facing today around the world. Information on market size raises the problem of increasing competitiveness and hampering market-leading sectors and market growth.

Get Exclusive Sample of Report on Seropositive Rheumatoid Arthritis Drug market is available @ https://reportsglobe.com/download-sample/?rid=107660

Some of the Important and Key Players of the Global Seropositive Rheumatoid Arthritis Drug Market:

Seropositive Rheumatoid Arthritis Drug market research report provides detailed information on the following aspects: Industry Size, Market Share, Growth, Segmentation, Manufacturers and Advancement, Key Trends, Market Drivers, Challenges, Standardization, Deployment Models, Opportunities, Strategies, Future Roadmaps and Annual Forecasts to 2027, etc. The report will help you also in understanding the dynamic structure of the Seropositive Rheumatoid Arthritis Drug market by identifying and analyzing market segments. The Global Seropositive Rheumatoid Arthritis Drug 2021 Industry Research Report has given the expected compound annual growth rate (CAGR) as a% of value for a given period of time and clearly helps the user make their decision based on the futuristic chart of the key players on the global Seropositive Rheumatoid Arthritis Drug market. The report introduces some of the major players in the global Seropositive Rheumatoid Arthritis Drug market and offers insightful information about the Seropositive Rheumatoid Arthritis Drug industry such as Business Overview, Seropositive Rheumatoid Arthritis Drug Market Product Segmentation, Revenue Segmentation, and the Latest Information. Developments.

Additionally, the Seropositive Rheumatoid Arthritis Drug market report includes a comprehensive strategic review as well as summarized studies of the growth, key factors, and market opportunity by which to evaluate the Seropositive Rheumatoid Arthritis Drug market and other important market related details on Seropositive Rheumatoid Arthritis Drug. The investigation of the research report also helps uncover accurate industry statistics depicting the ultimate model of the global Seropositive Rheumatoid Arthritis Drug market, including various types, applications, market growth structures, and opportunities. In addition, the study of the market research report provides an investigation and analysis of the past and current performance of the regional market that includes regions by department and subdivision. This regional analysis studies various key market parameters such as Seropositive Rheumatoid Arthritis Drug market growth rate in each region, production volume and capacity, market demand and supply, and return on investment (RoI).

Request a Discount on the report @ https://reportsglobe.com/ask-for-discount/?rid=107660

Some of the key questions answered in the report include-

1. What is the overall structure of the market?2. What was the historical value and what is the forecasted value of the market?3. What are the key product level trends in the market?4. What are the market level trends in the market?5. Which of the market players are leading and what are their key differential strategies to retain their stronghold?6. Which are the most lucrative regions in the market space?

Browse the complete report @ https://reportsglobe.com/product/global-seropositive-rheumatoid-arthritis-drug-market-insight-and-forecast/

Global Seropositive Rheumatoid Arthritis Drug market is segmented based by type, application and region.

Seropositive Rheumatoid Arthritis Drug Market Segmentation, By Type

Seropositive Rheumatoid Arthritis Drug Market Segmentation, By Application

The prime objective of this report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing. Deep researches and analysis were done during the preparation of the report. The readers will find this report very helpful in understanding the market in depth. The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts. The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better.

Global Seropositive Rheumatoid Arthritis Drugmarket Key Report Highlights:

This in-depth research documentation offers an illustrative overview of the entire market outlook with details on scope, executive summary, and market segments The report also includes sections on the competitive spectrum, highlighting major players, with a detailed assessment of supply chain management, competition dynamics, and growth objectives. Other crucial details on Porters Five Forces assessment, SWOT analysis, and data triangulation methods have also been included in the report. Other relevant details on production patterns, growth rate, market share of each of the segments have also been pinned in the report. The report also houses crucial analytical details on revenue share and sales projections, besides volumetric estimations of each of the product segments have also been highlighted in the report to encourage unfaltering market decisions and sustainable revenue streams in the global Seropositive Rheumatoid Arthritis Drug market.A dedicated chapter on COVID-19 analysis has therefore been included in this versatile report to encourage future-ready business discretion aligning with post-COVID-19 market environment.

Major Points from Table of Content:

1. Executive Summary2. Assumptions and Acronyms Used3. Research Methodology4. Seropositive Rheumatoid Arthritis Drug Market Overview5. Seropositive Rheumatoid Arthritis Drug Supply Chain Analysis6. Seropositive Rheumatoid Arthritis Drug Pricing Analysis7. Global Seropositive Rheumatoid Arthritis Drug Market Analysis and Forecast by Type8. Global Seropositive Rheumatoid Arthritis Drug Market Analysis and Forecast by Application9. Global Seropositive Rheumatoid Arthritis Drug Market Analysis and Forecast by Sales Channel10. Global Seropositive Rheumatoid Arthritis Drug Market Analysis and Forecast by Region11. North America Seropositive Rheumatoid Arthritis Drug Market Analysis and Forecast12. Latin America Seropositive Rheumatoid Arthritis Drug Market Analysis and Forecast13. Europe Seropositive Rheumatoid Arthritis Drug Market Analysis and Forecast14. Asia Pacific Seropositive Rheumatoid Arthritis Drug Market Analysis and Forecast15. Middle East & Africa Seropositive Rheumatoid Arthritis Drug Market Analysis and Forecast16. Competition Landscape

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @ https://reportsglobe.com/need-customization/?rid=107660

How Reports Globe is different than other Market Research Providers:

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Contact us:

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email: [emailprotected]

Web: reportsglobe.com

Visit link:
Seropositive Rheumatoid Arthritis Drug Market Size By Analysis, Key Vendors, Regions, Type and Application, and Forecasts to 2027 - NeighborWebSJ

Read More...

Aker BioMarine collaboration looks to boost omega-3 oil delivery to brain and eyes – NutraIngredients.com

January 14th, 2021 11:58 am

The collaboration looks to support Akers new delivery platform, LYSOVETA that is based on lysophosphatidylcholine (LPC)-bound EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) derived from krill.

The complex enables EPA and DHA to pass through the blood-brain barrier and enter the brain as well as enriching the retina to improve ocular health.

The LPC transporter allows EPA and DHA to enter the brain and the retina, explains Papasani Subbaiah, professor of medicine, biochemistry and molecular genetics at the UIC College of Medicine.

We have demonstrated that LPC- bound EPA and DHA from krill oil have a huge beneficial effect on the uptake levels in these organs.

As part of the agreement, the Oslo-based firm will receive an exclusive license to the current intellectual property resulting from Professor Subbaiahs work on LPC-EPA/DHA.

Aker will also supply the UIC team with LPC-bound EPA and DHA derived from Antarctic krill to further their research.

Prof Subbaiah was the lead author of a recent study looking into LPC-EPAs ability to tackle disorders such as depression by increasing levels of EPA levels in the brain.

He commented that boosting EPA levels in the brain through consuming EPA had proven difficult because the amount of EPA that would need to be ingested to show increases in brain EPA levels was quite large - 40 to 50 millilitres (ml) daily.

Our partnership with the University of Illinois Chicago marks the first step in establishing a strong network of collaborators within the LPC-bound EPA and DHA field, says Matts Johansen, CEO, Aker BioMarine.

We will continue to explore the potential of LPC-bound EPA and DHA from krill, to gain a broader and in-depth understanding of how LYSOVETA can benefit brain and eye function.

There is no better way to kick this off than with a world-leading research team on this subject by our side,

Launched in November 2020, the firm looks to apply the LYSOVETA platform to healthy ageing as well as eye and brain health.

This development is especially applicable during the early years and late in life, where the most pronounced structural and cognitive changes occur.

Research suggests that targeted delivery of essential fatty acids may be of particular importance in periods of accelerated alterations in brain structure.

Aker states that further research on the role of LPC-EPA/DHA from a lifespan perspective could therefore provide benefits both to individuals and to society as a whole.

The firm revealed that it was to scale up production capacity of the molecule at its manufacturing plant in Houston with regulatory approval for the dietary supplement version of LYSOVETA expected by the end of 2022.

Aker added it was also seeking partners to pursue commercial opportunities in the pharmaceutical and infant formula segment.

The agreement with UIC also looks to be the first in a number of academic-industry partnerships as Aker revealed its intentions to reaching out to universities and research organisations with material and knowhow to stimulate further research.

"It is important to bring our findings into the real world, to test and prove the commercial potential of LPC-bound EPA and DHA in terms of its benefits on human health, adds Hyunjin Kim, Associate Technology Manager at UICs Office of Technology Management.

We are excited about this collaboration with Aker BioMarine, a partner whose products are firmly rooted in science.

Original post:
Aker BioMarine collaboration looks to boost omega-3 oil delivery to brain and eyes - NutraIngredients.com

Read More...

The new age (not that sort) of crystals – Financial Times

January 14th, 2021 11:58 am

Whether or not you feel your chakras could do with some realignment, its unlikely the term crystal healing has passed you by. The hashtag crops up 5.3m times on Instagram, and Google searches for the term have risen 60 per cent over the past decade. The alternative-wellness trend is based on the theory that crystals such as rose quartz or black obsidian favourites of Gwyneth Paltrow and Victoria Beckham rebalance the bodys electromagnetic field.

While demand for diamonds could have dropped by as much as 25 per cent in 2020, the value of crystals such as quartz, amethyst, citrine and malachite is holding steady. Our first standalone mineral sale was in 2014 and we took 800,000, says James Hyslop, Christies head of natural history. Our sale last October did 1.4m. It is very much amarket that is on the up.

But its not the new wave of New Age spirituality thats driving the high end of the market, says Rob Lavinsky, a doctor of molecular genetics and founder of Dallas-based crystal dealership The Arkenstone. Its a new class of collectors. Theyre not scientists, they didnt start collecting as children as rockhounds buying $5 minerals. They are coming in from other collectable worlds coins, cars, antiques, art and have no problem paying 10,000, or $100,000 for quality. The finest minerals on his website typically range from $100,000 to $500,000. The absolute top things, including a few over the $2m mark, are not listed online.

The type of systematic collecting pioneered by18th-century European aristocrats for their Wunderkammern has sort of gone, agrees New York dealer Daniel Trinchillo, founder of Mardani Fine Minerals, adding that todays major mineral players include Salim Edd, whose collection opened Beiruts Mineral Museum (MIM) in 2013, and GuyLalibert, founder of Cirque du Soleil. Theyare looking for works of art amazingly beautiful, sculptural objects, says fellow New York dealer Stuart Wilensky.

We never know what will come out of the ground tomorrow, Wilensky adds. And this has a dynamic effect on collecting. Most popular are the colourful minerals tourmalines and calcites, even amethysts and quartzes. And fluorite in particular. It comes in nearly every colour, from hundreds of locations around the world, explains Wilenskys website, where a 4.5cm-high specimen of lavender-hued cubic fluorite from China is $3,975, and asought-after combination of pink fluorite and smoky quartz from Switzerland is $855,000.

Recently, the field has come under scrutiny for its supply chains, sustainability and wage thresholds. Our business is not regulated, says Wilensky. But the focus seems to be inspiring systemic change. London seller Shes Lost Control has a Sustainable Mining Initiative with a Brazilian mine. Lavinsky says he consciously drives a price spiral in source countries. And Ian Bruce of Crystal Classics, a leading UK dealer, now operates Europes only specimen mine, in the north of England. We employ 14 full-time miners, he says. The market is now so strong that its commercially viable and were seeing the same thing in the US, South America, Asia, Australia.

As well as new finds, the market incorporates antique specimens where provenance comes into play. Illustrious former owners run from prolific 19th-century collector Stephan von Habsburg-Lothringen whose specimen labels, printed by the Budapest mint, are highly prized to Yves Saint Laurent, whose rock crystals, pyrite clusters and amethyst geodes were auctioned by Christies in 2009.

The auction houses including Sothebys and Heritage Auctions in Dallas are relative newcomers to the realm. As such, We havent seen good specimens hit the auction world yet, posits Bruce. His Somerset showroom is a destination for CEOs and international celebrities, who might leave with an aquamarine from Pakistan ($100,000) or an African druzy chrysocolla ($90,000). One of Bruces most serious customers has 130 treasures, housed in a custom-made glass-fronted cabinet. I go for aesthetics. I love the sheer magic of how theyve formed in some cases a billion or more years ago and the sense of permanence. Pointing to his collection, he says, Thats one of the rarest forms of beryl, from Utah.

The London home of spatial designer Robert Storey shows a more relaxed side of the collector coin. I have a bunch of crystals around my house, he says of the pieces bought on his travels and grouped casually on tabletops. I dont know much about their metaphysical qualities, I just love the way they look. My favourite is azurite-malachite. Its green and blue I like to think of it as land and water.

To capitalise on the growing market for less-rare specimens, and those with a happenstance approach to collecting, Lavinsky runs MineralAuctions.com, where bids start at $10: At $500 to $5,000, you can build a really fun collection. More fun still, for some collectors at least, is to turn sourcing crystals into an experience. In the US, you can do the mining yourself pay-to-dig mines are undergoing a resurgence, as modern-day gem hunters seek their fortunes. Or just a nice chunk of quartz and a bit of a fossick.

MIM Museum, Beirut mim.museum. Natural History Museum, London nhm.ac.uk

The Mineralogical Record Bi-monthly magazine; mineralogicalrecord.com

The Arkenstone irocks.com. Christies christies.com. Crystal Classics crystalclassics.co.uk. Mardani Fine Minerals mardanifineminerals.com. Shes Lost Control sheslostcontrol.co.uk. Tucson Gem & Mineral Show tgms.org; next show, February 2022. Wilensky wilenskyminerals.com

View original post here:
The new age (not that sort) of crystals - Financial Times

Read More...

Researchers seek to help prevent and treat disease by studying the effects of exercise – University of Virginia The Cavalier Daily

January 14th, 2021 11:58 am

University researchers are taking part in an unprecedented research project centered on the biological effects of exercise after receiving a grant from the National Institutes of Health and joining a national consortium of research institutions that includes Stanford University, the University of Florida and Duke University. They are applying Big Data and machine learning techniques, which are methods used to analyze large amounts of often complex data, to a robust molecular map in order to identify the prominent molecules involved in exercise. The long-term goal of modifying those molecules is to develop medical interventions which mimic the effects of exercise in the body.

In 2010, Zhen Yan, director of the Center for Skeletal Muscle Research at the Universitys Robert M. Berne Cardiovascular Research Center, and other prominent scientists were invited to a roundtable discussion hosted by the NIH to discuss the future of exercise research. The researchers addressed the mutual consensus that regular physical activity is crucial to fighting numerous chronic conditions, including cardiovascular diseases, diabetes, obesity and depression, among others. The scientists at the conference thus agreed on the importance of conducting further research to determine the deeper molecular causes facilitating exercises well-documented benefits.

Exercise seems to be a regular physical activity and seems to be one of the most effective interventions, but the million dollar question is why exercise is so good, Yan said.

In 2016, the NIHs constituent institutions allocated a total of $170 million to form the Molecular Transducers of Physical Activity Consortium, which consists of multiple educational institutions including the University. MoTrPAC aims to collectively track the molecular mechanisms elicited by exercise in order to better understand how it impacts the health of the bodys tissues and organs.

Identifying and understanding the particular mechanisms instigated by exercise may allow healthcare providers to apply the findings to prescribe more specific exercise recommendations for their patients. Knowing the exact mechanisms could also allow for treatments which imitate the beneficial bodily effects of exercise for those with limited mobility.

If we understand the mechanism, we will not only be able to ... manipulate or employ exercise intervention, but we can also use modern medical science to come up with strategies that mimic exercise for people who cannot for whatever the reason exercise regularly, Yan said.

The Universitys research team is building their studies off results from NIHs phase one trials, which involved constructing a molecular map of biological molecules which have been shown to improve and preserve the health of the bodys tissues and organs. Phase one used animal studies and multi-omics, which is a methodology they used to analyze bulks of molecular data.

The first step of Yan and the team is to take this molecular map from the NIH and filter through it to identify the exact molecular mechanism responsible for exercises health benefits. The team is utilizing machine learning algorithms and Big Data methods to search for the particular molecules that are produced or released into circulation upon performing physical activity.

Our task is to find a specific route in that map that is critical for this journey, Yan said.

Upon narrowing down the search to the anticipated candidate molecules, the next step would be to manipulate their expression in animal models by using gene editing to activate or inactivate the expression of the identified molecules in animals. The physiological response of the animals would be consequently observed to determine if the targeted molecule is indeed responsible for eliciting the physiological responses caused by exercise.

The research team is composed of scientists from multiple disciplines, including genetics, bioinformatics and neuroscience, in attempts to gain an increasingly holistic understanding of the mechanisms responsible for exercises benefits.

Dr. John Lukens, assistant professor and researcher at Universitys Department of Neuroscience and the Center for Brain Immunology and Glia, is focusing on how the presence of exercise strengthens connections in the brain and results in improved cognitive function. He plans to change the expression of the molecular pathways identified by bioinformatics methods and consequently put the animals through cognition tasks.

[Exercise] has also been shown to be really important to prevent things like cognitive decline and things like Alzheimer's disease and that's been appreciated for a long time, but nobody really knows how that works, Lukens said.

Adding a neurological angle to Yans project, Lukens plans to study the animals behavior and quantity of neurons in their brains to gain a deeper understanding of how performing exercise impacts mental health conditions such as anxiety and depression.

[We will conduct] post analysis, looking at the brains to see if they have any kind of loss of neurons, neurodegeneration, which is the underlying cause of most known brain disorders or mental diseases, Lukens said.

In addition, combining the effects of regularly performing exercise with stimulation of target molecular pathways will open up new experimental possibilities as factors like changes in hormone levels, oxygen intake and sleep are already induced by the act of exercise alone.

We just dont understand the molecular players involved, but if we can identify those, combining exercise and target pathways, you might have a synergistic effect that can really make a difference in somebodys life, Lukens said.

A challenge which the team expects to encounter is effectively using bioinformatics to sift through NIHs broad molecular dataset in order to identify intended beneficial pathways.

Yan believes that the current pandemic highlights the importance of maintaining a healthy lifestyle that incorporates exercise.

If anything, the COVID-19 pandemic is a wake-up call that we should really take advantage of a healthy lifestyle, including regular exercise to stay healthy and be prepared to deal with the current pandemic and future challenges, Yan said.

More:
Researchers seek to help prevent and treat disease by studying the effects of exercise - University of Virginia The Cavalier Daily

Read More...

CRISPR and the Splice to Survive – The New Yorker

January 14th, 2021 11:58 am

Odin, in Norse mythology, is an extremely powerful god whos also a trickster. He has only one eye, having sacrificed the other for wisdom. Among his many talents, he can wake the dead, calm storms, cure the sick, and blind his enemies. Not infrequently, he transforms himself into an animal; as a snake, he acquires the gift of poetry, which he transfers to people, inadvertently.

The Odin, in Oakland, California, is a company that sells genetic-engineering kits. The companys founder, Josiah Zayner, sports a side-swept undercut, multiple piercings, and a tattoo that urges: Create Something Beautiful. He holds a Ph.D. in biophysics and is a well-known provocateur. Among his many stunts, he has coaxed his skin to produce a fluorescent protein, ingested a friends poop in a D.I.Y. fecal-matter transplant, and attempted to deactivate one of his genes so that he could grow bigger muscles. (This last effort, he acknowledges, failed.) Zayner calls himself a genetic designer and has said that his goal is to give people access to the resources they need to modify life in their spare time.

The Odins offerings range from a Biohack the Planet shot glass, which costs three bucks, to a genetic engineering home lab kit, which runs almost two thousand dollars and includes a centrifuge, a polymerase-chain-reaction machine, and an electrophoresis gel box. I opted for something in between: the bacterial CRISPR and fluorescent yeast combo kit, which set me back two hundred and nine dollars. It came in a cardboard box decorated with the companys logo, a twisting tree circled by a double helix. The tree, I believe, is supposed to represent Yggdrasil, whose trunk, in Norse mythology, rises through the center of the cosmos.

Inside the box, I found an assortment of lab toolspipette tips, petri dishes, disposable glovesas well as several vials containing E. coli and all Id need to rearrange its genome. The E. coli went into the fridge, next to the butter. The other vials went into a bin in the freezer, with the ice cream.

Genetic engineering is, by now, middle-aged. The first genetically engineered bacterium was produced in 1973. This was soon followed by a genetically engineered mouse, in 1974, and a genetically engineered tobacco plant, in 1983. The first genetically engineered food approved for human consumption, the Flavr Savr tomato, was introduced in 1994; it proved such a disappointment that it went out of production a few years later. Genetically engineered varieties of corn and soy were developed around the same time; these, by contrast, have become more or less ubiquitous.

In the past decade or so, genetic engineering has undergone its own transformation, thanks to CRISPRshorthand for a suite of techniques, mostly borrowed from bacteria, that make it vastly easier for biohackers and researchers to manipulate DNA. (The acronym stands for clustered regularly interspaced short palindromic repeats.) CRISPR allows its users to snip a stretch of DNA and then either disable the affected sequence or replace it with a new one.

The possibilities that follow are pretty much endless. Jennifer Doudna, a professor at the University of California, Berkeley, and one of the developers of CRISPR, has put it like this: we now have a way to rewrite the very molecules of life any way we wish. With CRISPR, biologists have already createdamong many, many other living thingsants that cant smell, beagles that put on superhero-like brawn, pigs that resist swine fever, macaques that suffer from sleep disorders, coffee beans that contain no caffeine, salmon that dont lay eggs, mice that dont get fat, and bacteria whose genes contain, in code, Eadweard Muybridges famous series of photographs showing a horse in motion. Two years ago, a Chinese scientist, He Jiankui, announced that he had produced the worlds first CRISPR-edited humans, twin baby girls. According to He, the girls genes had been tweaked to confer resistance to H.I.V., though whether this is actually the case remains unclear. Following his announcement, He was fired from his academic post, in Shenzhen, and sentenced to three years in prison.

I have almost no experience in genetics and have not done hands-on lab work since high school. Still, by following the instructions that came in the box from the Odin, in the course of a weekend I was able to create a novel organism. First I grew a colony of E. coli in one of the petri dishes. Then I doused it with the various proteins and bits of designer DNA Id stored in the freezer. The process swapped out one letter of the bacterias genome, replacing an A (adenine) with a C (cytosine). Thanks to this emendation, my new and improved E. coli could, in effect, thumb its nose at streptomycin, a powerful antibiotic. Although it felt a little creepy engineering a drug-resistant strain of E. coli in my kitchen, there was also a definite sense of achievement, so much so that I decided to move on to the second project in the kit: inserting a jellyfish gene into yeast in order to make it glow.

The Australian Centre for Disease Preparedness, in the city of Geelong, is one of the most advanced high-containment laboratories in the world. It sits behind two sets of gates, the second of which is intended to foil truck bombers, and its poured-concrete walls are thick enough, I was told, to withstand a plane crash. There are five hundred and twenty air-lock doors at the facility and four levels of security. Its where youd want to be in the zombie apocalypse, a staff member told me. Until recently, the center was known as the Australian Animal Health Laboratory, and at the highest biosecurity levelBSL-4there are vials of some of the nastiest animal-borne pathogens on the planet, including Ebola. (The laboratory gets a shout-out in the movie Contagion.) Staff members who work in BSL-4 units cant wear their own clothes into the lab and have to shower for at least three minutes before heading home. The animals at the facility, for their part, cant leave at all. Their only way out is through the incinerator is how one employee put it to me.

About a year ago, not long before the pandemic began, I paid a visit to the center, which is an hour southwest of Melbourne. The draw was an experiment on a species of giant toad known familiarly as the cane toad. The toad was introduced to Australia as an agent of pest control, but it promptly got out of control itself, producing an ecological disaster. Researchers at the A.C.D.P. were hoping to put the toad back in the bottle, as it were, using CRISPR.

A molecular biologist named Mark Tizard, who was in charge of the project, had agreed to show me around. Tizard is a slight man with a fringe of white hair and twinkling blue eyes. Like many of the scientists I met in Australia, hes from somewhere elsein his case, England. Before getting into amphibians, Tizard worked mostly on poultry. Several years ago, he and some colleagues at the center inserted a jellyfish gene into a hen. This gene, similar to the one I was planning to plug into my yeast, encodes a fluorescent protein. A chicken in possession of it will, as a consequence, emit an eerie glow under UV light. Next, Tizard figured out a way to insert the fluorescence gene so that it would be passed down to male offspring only. The result is a hen whose chicks can be sexed while theyre still in their shells.

Tizard knows that many people are freaked out by genetically modified organisms. They find the idea of eating them repugnant, and of releasing them into the world anathema. Though hes no provocateur, he, like Zayner, believes that such people are looking at things all wrong. We have chickens that glow green, Tizard told me. And so we have school groups that come, and when they see the green chicken, you know, some of the kids go, Oh, thats really cool. Hey, if I eat that chicken, will I turn green? And Im, like, You eat chicken already, right? Have you grown feathers and a beak?

Anyway, according to Tizard, its too late to be worried about a few genes here and there. If you look at a native Australian environment, you see eucalyptus trees, koalas, kookaburras, whatever, he said. If I look at it, as a scientist, what Im seeing is multiple copies of the eucalyptus genome, multiple copies of the koala genome, and so on. And these genomes are interacting with each other. Then, all of a sudden, ploomph, you put an additional genome in therethe cane-toad genome. It was never there before, and its interaction with all these other genomes is catastrophic. It takes other genomes out completely. He went on, What people are not seeing is that this is already a genetically modified environment. Invasive species alter the environment by adding entire creatures that dont belong. Genetic engineers, by contrast, just alter a few stretches of DNA here and there.

What were doing is potentially adding maybe ten more genes onto the twenty thousand toad genes that shouldnt be there in the first place, and those ten will sabotage the rest and take them out of the system and so restore balance, Tizard said. The classic thing people say with molecular biology is: Are you playing God? Well, no. We are using our understanding of biological processes to see if we can benefit a system that is in trauma.

Formally known as Rhinella marina, cane toads are a splotchy brown, with thick limbs and bumpy skin. Descriptions inevitably emphasize their size. Rhinella marina is an enormous, warty bufonid (true toad), the U.S.Fish and Wildlife Service notes. The U.S.Geological Survey observes that large individuals sitting on roadways are easily mistaken for boulders. The biggest cane toad ever recorded was fifteen inches long and weighed six poundsas much as a chubby chihuahua. A toad named Big Bette, who lived at the Queensland Museum, in Brisbane, in the nineteen-eighties, was nine and a half inches long and almost as wideabout the size of a dinner plate. The toads will eat almost anything they can fit in their oversized mouths, including mice, dog food, and other cane toads.

Cane toads are native to South America, Central America, and the southernmost tip of Texas. In the mid-eighteen-hundreds, they were brought to the Caribbean. The idea was to enlist the toads in the battle against beetle grubs, which were plaguing the regions cash crop, sugar cane. (Sugar cane, too, is an import; it is native to New Guinea.) From the Caribbean, the toads were shipped to Hawaii. In 1935, a hundred and two toads were loaded onto a steamer in Honolulu, headed for Australia. A hundred and one survived the journey and ended up at a research station in sugar-cane country, in northeast Queensland. Within a year, theyd produced more than 1.5 million eggs. (A female cane toad can produce up to thirty thousand eggs at a go.) The resulting toadlets were intentionally released into the regions rivers and ponds.

Its doubtful that the toads ever did the sugar cane much good. Cane beetles perch too high off the ground for a boulder-size amphibian to reach. This didnt faze the toads. They found plenty else to eat, and continued to produce toadlets by the truckload. From a sliver of the Queensland coast, they pushed north, into the Cape York Peninsula, and south, into New South Wales. Sometime in the nineteen-eighties, they crossed into the Northern Territory. In 2005, they reached a spot known as Middle Point, in the western part of the Territory, not far from the city of Darwin.

Along the way, something curious happened. In the early phase of the invasion, the toads were advancing at the rate of about six miles a year. A few decades later, they were moving at the pace of twelve miles a year. By the time they hit Middle Point, theyd sped up to thirty miles a year. When researchers measured the individuals at the invasion front, they found out why. The toads had significantly longer legs than the toads back in Queensland, and this trait was heritable. The Northern Territory News played the story on its front page, under the headline SUPER TOAD. Accompanying the article was a doctored photo of a cane toad wearing a cape. It has invaded the Territory and now the hated cane toad is evolving, the newspaper gasped. Contra Darwin, it seemed, evolution could be observed in real time.

Read more:
CRISPR and the Splice to Survive - The New Yorker

Read More...

Yourgene Health : 11 January 2021 – Clarigene SARS-CoV-2 Product Update and Partnerships with CityDoc and ReCoVa-19 + – Marketscreener.com

January 14th, 2021 11:58 am

Manchester, UK - 11 January 2021:Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that following the Company's statement on 24 December 2020, regarding the new virus strain (VUI-202012/01 SARS-CoV-2 variant), Yourgene's wet lab testing is now complete and has confirmed that the performance of the ClarigeneSARS-CoV-2 assay is not impacted by any currently known mutations in the VUI-202012/01 strain.

The wet lab testing followed a detailedin silico(Computer) analysis of the mutations in the new SARS-CoV-2 variant, to assess the reliability of Yourgene's existing Clarigeneproduct. Unlike many other assays on the market, the ClarigeneSARS-CoV-2 assay does not rely on amplification of the S gene, where one of the key VUI-202012/01 variants (N501Y) is located, in this new virulent strain. The Company has also implemented an ongoing rigorous internal surveillance programme to ensure continued monitoring for the development of new viral strains. This includes database monitoring for SARS-CoV-2 variants with mutations in the N and the E gene which fall around the assay primers and probes, as well as impact assessment on these mutations on assay performance, evaluated byin silicoanalysis and wet lab confirmation.

Following the confirmation of the performance of the ClarigeneSARS-CoV-2 assay against the new virus strain, Yourgene have partnered with CityDoc Medical Limited ("CityDoc"), a 15-year old healthcare business and one of the UK's largest private vaccination and medical testing companies with over 150+ clinics across the UK, to oversee the customer management and offer responsive clinical support for Yourgene's Clarigenetest, for the UK Government's Test To Release for international travellers scheme. CityDoc will manage the e-commerce function and logistics by allowing customers to order a sample collection kit and returning the test sample to the Yourgene laboratory. In addition, another key customer, ReCoVa-19 Limited works alongside Yourgene and CityDoc to provide access to their customer-facing COVID testing and wellness monitoring app, which enables sample tracking and customers to access their test results.

Lyn Rees, CEO of Yourgene commented:"We are pleased to confirm that our Clarigenetest is not compromised by the recently analysed mutations in the SARS-CoV-2 virus and believe that our ongoing internal surveillance for new virus strains shows our commitment to offering our customers the quality products they expect and deserve. We have a great and reliable product in the Clarigene test and look forward to working with CityDoc and ReCoVa-19 Limited, in order to support the economy by aiding the travel industry's return to normality."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. The Directors of the Company take responsibility for this announcement.

Lyn Rees, Chief Executive OfficerBarry Hextall, Chief Financial OfficerJoanne Cross, Director of Marketing

investors@yourgene-health.com

Cairn Financial Advisers LLP (NOMAD)Liam Murray / James Caithie / Ludovico Lazzaretti

Tel: +44 (0)20 7213 0880

N+1 Singer (Joint Corporate Broker)Aubrey Powell / Tom Salvesen / George Tzimas

Tel: +44 (0)20 7496 3000

Nicholas Moore / Matthew Blawat / Ben Maddison

Tel: +44 (0)20 7710 7600

Paul McManus / Lianne Cawthorne

Mob: 07980 541 893 Mob: 07584 391 303

About Yourgene Health plc

Yourgene is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.

Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, for reproductive health and molecular genetics. The Group's products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene's commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.

Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene is also extending its genetic testing offering into oncology.

Yourgene is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information, visitwww.yourgene-health.comand follow us on twitter@Yourgene_Health.

Forward-Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

Disclaimer

Yourgene Health plc published this content on 11 January 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 January 2021 08:17:03 UTC

Read more:
Yourgene Health : 11 January 2021 - Clarigene SARS-CoV-2 Product Update and Partnerships with CityDoc and ReCoVa-19 + - Marketscreener.com

Read More...

The meat spot – Japanese people may have gained longevity by balancing their diets | Graphic detail – The Economist

January 14th, 2021 11:56 am

Japans rate of strokes fell during a period when it began eating a bit of meat

Jan 16th 2021

TANAKA KANE is one of humanitys great outliers. On January 2nd she became the third person ever to turn 118, according to the Gerontology Research Group, a team of academics. She is also the first citizen of Japan to reach 118but is unlikely to be the last. The country has the worlds longest life expectancy, and 80,000 centenarians.

Mrs Tanaka is an outlier for another reason, too. She claims to love chocolate and fizzy drinks, setting her apart from most of her compatriots. Japan has long had one of the lowest sugar-consumption rates in the OECD, a club of mainly wealthy countries.

The unusual longevity enjoyed in Japan is often credited to diet. Yet the idea that the country has extended lifespans by entirely avoiding the Wests sinful culinary delights may be too simple. In fact, recent studies imply that one key to its success may be that its peoples diets have shifted over time towards Western eating patterns.

Japan was not always a longevity champion. In 1970 its age-adjusted mortality rates were average for the OECD. Although its levels of cancer and heart disease were relatively low, it also had the OECDs highest frequency of cerebrovascular deaths, caused by blood failing to reach the brain.

In 1970-90, however, Japans cerebrovascular mortality rate fell towards the OECD average. With world-beating numbers on heart disease and fewer strokes, Japan soared up the longevity league table.

How did Japan overcome its cerebrovascular woes? Some of its gains simply mirror better treatments and reductions in blood pressure around the world, notes Thomas Truelsen of the University of Copenhagen.

However, another cause may be diets. Japan largely banned meat for 1,200 years, and still consumes relatively little meat and dairy. Too much of these can be damaging, since they contain saturated fatty acids, which correlate to heart disease. Studies have also tied eating lots of processed red meat to a greater risk of stroke. But too little may be unwise as well, because they provide cholesterol that may be needed for blood-vessel walls. In a study of 48,000 Britons, vegetarians were unusually resistant to heart disease, but prone to strokes.

In theory, a dearth of animal-based food could have contributed to Japans historical cerebrovascular mortality. In 1960-2013, as the countrys deaths from strokes tumbled, its annual meat intake rose from near zero to 52kg per person (45% of Americas level). Tsugane Shoichiro of the National Cancer Centre in Tokyo says that his compatriots may need meat and dairy to keep their blood vessels robustthough not so much that those vessels get clogged.

Some empirical evidence supports this view. One paper from the 1990s found that the parts of Japan where diets had changed most also had the biggest drops in cerebrovascular mortality. Another study, which tracked 80,000 Japanese people in 1995-2009, showed that strokes were most common among those who ate the least chops and cream. Although Japans decline in cerebrovascular deaths could stem entirely from other causes, these data suggest that nutritional shifts may have helped.

The unhappy irony is that Japans health gains, paired with a low birth rate, threaten its economy. By 2060, 40% of Japanese could be 60 or older. That would yield more birthday cakes with 118 candlesand fewer great-grandchildren to blow them out.

Sources: WHO; FAOSTAT; OECD; UN

This article appeared in the Graphic detail section of the print edition under the headline "The meat spot"

Go here to see the original:
The meat spot - Japanese people may have gained longevity by balancing their diets | Graphic detail - The Economist

Read More...

The 17 Best Longevity Tips Experts Taught Us in 2020 – Well+Good

January 14th, 2021 11:56 am

In recent years, the motivation for healthy habits like veggie-heavy diets and regular exercise has shifted from present-day benefits to those more long-term in nature. And were not just interested in extending our lifespan, but our health span, tooaka the length of time we are not only alive but alive and well. Most of us want to die with our boots on, as my grandfather would sayable in both mind and body.

As such, longevity research has become a major focus in the wellness world and this year, we learned quite a bit about how to optimize our daily lives now for the benefit of our future selves. Below, a rundown of the best tips weve accumulated in 2020 for living your healthiest life into your 80s and beyondbecause theres a lot to live well for just ask President-Elect Joe Biden, who is 78!

1. Exercise this many times per week

Its no secret that human beings were designed to be a lot more active than most of us currently are in our modern-day, screen-heavy existences; however, you dont need to give up hope of a long life if youre pressed for tons of time to move each week. This year, a new study published inJAMA Internal Medicinefound that those who engage in moderate or vigorous exercise 150 minutes per weekhad lower all-cause mortality.

That translates to just 22 minutes of moderate-to-intense exercise per day. Those who got these 150 minutes per week showed a lower risk of early death from all-cause mortality, cardiovascular disease mortality, and cancer mortality.

Benefits were especially notable in those who tended toward the more rigorous side of the equation, opting for running, High Intensity Interval Training (HIIT) routines, or something equally as taxing. The takeaway there is that if you are doing lower-impact exercises, it might help to throw a few more hardcore (think: quick and dirty) fitness routines into the mix as well. Not sure where to start? Here are nine such workouts you can try now (or January 1, because resolutions).

2. This particular workout format packs the best longevity punch

Any exercise is better than none, so if theres a format you love and that gets you moving, you should one hundred percent stick to it. But if youre open to new things or are already a devotee, research this year shows that HIIT workouts are the most effective form of fitness from a longevity standpoint.

The study looked at the effects of two weekly HIIT workouts per week on 70 to 77 year-olds and found that all-cause mortality was 36 percent lower in that group than in the studys control group (which did whatever kind of exercise they liked). Thirty-six percent!

The specific HIIT routine the studys participants engaged in was the 44 format, which divides each workout into a 10-minute warm-up period followed by four high-intensity intervals. Each interval consists of one to two minutes of extreme exertion, at about 90 percent of maximum heart rate, followed by a three-minute period at about 60 percent of heart rate. The session then concludes with a cool down period. If you want toe try one out, here are four to get you started.

3. If your workouts dont include this one move, they probably should

Technically, research just shows that if you can do this one move easily, that in and of itself is a good indication of longevity: the squat. So while this doesnt necessarily show that doing squats will increase your lifespan, it stands to reason that one way to ensure you can do them easily is to, well, do themand frequently.

One of the reasons its such a good exerciseboth to practice frequently and as a longevity predictor is that its functional, meaning we sort of need to be able to execute squat-like movements regularly in everyday life when, for example, we move from sitting to standing. Plus, we sit too much, and therefore the parts of our bodies, e.g. the glutes, which squats activate do not get nearly the amount of work they were built to take on.

Its critical, howeverfor knee health especiallythat you squat with proper form; heres how.

4. Cardio is not to be overlooked, either

Its not always possible for everyone to engage in high-impact exercise like HIIT or running, but that doesnt mean theyre screwed from a longevity perspective. In some cases, people might want to choose exercises that are gentler on their joints, which is not the same thing as being easy.

According to a cardiologist, there are five types of low-impact cardio thatll work you out hard without irritating aging or injured parts of your body: swimming, walking, cycling, rowing, and elliptical. Or, heres a 25-minute low-impact cardio workout you can try from home today.

5. Overall, your workout routines should include these 3 pillars

Ultimately, the best fitness routines are a mix of a number of different modalities, and exercising for longevity is no different. According toAleksandra Stacha-Fleming, founder of NYCs Longevity Lab, a gym that works with people of all ages to create workouts that help their bodies age properly, your regular workouts should typically include a smattering of the following: cardio, for your heart; strength-training, for your bones; and anything that works your flexibility and mobility, e.g. yoga. Get workout vids for each here.

1. Always keep these 6 foods on hand in your fridge

According to Dan Buettner, longevity expert and author ofThe Blue Zones Kitchen, the longest-living people in the world dont obsess over or restrict what they eat; however, they naturally consume nutrient-dense foods as a way of life. The six such foods Buettner thinks you should stock up on ASAP to follow their lead are nuts, vegetables, fruit, tofu, fish, and alt-milk. Find out more about why here.

You might want to add a jar of canned hearts of palm to your shopping list the next time youre try to stock your fridge, too. The ingredient is nutrient-dense, antioxidant-rich, and packed with minerals like potassium, iron, phosphorus, and zinc. Most importantly, its Blue Zones diet-approved, meaning its a longevity-booster, too. Try these 9 recipes to make use of your next hearts of palm haul.

2. Meanwhile, these 5 foods should go in your freezer

Buettner also has thoughts on what should be found in your freezer if you hope to emulate the worlds centenarians. His top five picks include a lot of the same things you should simultaneously keep fresh in your fridge, like fruits and vegetables, and nuts fall into both categories, too. Additionally, Buettner recommends keeping bread (bless you, Buettner!) and whole grains on ice, too. Get a few recipes made with each ingredient on this Buettners freezer list here.

3. Pack these in your pantry

Buettner even shared what he keeps in his own kitchen specifically when it comes to his pantry. What youll find there includes staples such as beans, legumes, whole grains (specifically steel-cut oats and brown rice), nuts, and seeds. You should keep canned greens in your pantry, too.

4. Herbs and spices are oh-so-important, too

Excess inflammation is an enemy of healthy aging, and plants are packed with anti-inflammatory and antioxidant properties. According to herbalist Rachelle Robinett, nutrient-dense herbs are, therefore, a great supplement for anyone looking to enhance the longevity benefits of their diet. Specifically, she recommends ginger, turmeric, spirulina, chili peppers, and ginsengfind out more on why here.

People in the Blue Zone of Okinawa, Japan, also consume an herb called otani-watari, which can be boiled and added to stir-fries, soups, and salad.

4. This one-pot recipe is a longevity experts favorite go-to meal

Whatever Buettner, whos made his lifes work longevity, is eating regularly, Ill have, too. Fortunately, this year he shared his favorite go-to meal, which just so happens to be a one-pot Ikarian Longevity Stew packed with legumes and superstar veggies. Get the recipe here.

5. Overall, its this popular diet that wins the day with respect to longevity

You may have noticed a theme in the above tips, which is that they heavily emphasize fruits, vegetables, nuts, legumes, and whole grains; however, the longest-living people in the world arent necessarily vegans. Instead, they adhere to the Mediterranean Diet, and recent research has strengthened the link between it and longevity.

The study found that the Mediterranean diet may be linked to lowering inflammation markers and increasing both brain function and gut healthand therefore improving the aging process overall.

Essentially, the Mediterranean diet does call for substantial amounts of those aforementioned fruits, veggies, whole grains, and nuts. It also adds olive oil as a key component alongside fish and encourages a reduction in the consumption of red meat and saturated fats.

Need a little help making shifting your eating habits to better reflect this diet? Try the Blue Zones specific daily, weekly, and monthly guide for eating more like the longest-living humans on the planet.

6. To keep it simpler still, follow these golden rules of eating for longevity

If all of the above sounds like a lot, consider this; according to Buettner, there are six golden consumption rules to follow if you want to live longer, and TBH, theyre not very restrictive. The first is to drink wine after 5 p.m., ideally with friends or loved ones and a meal. (Um, twist my arm!) The second is to eat mostly plant-based foods, which at this point feels a bit repetitive, so duh. The third is to forget fad-diet brainwashing and carbo load to your hearts desire, as long as your carbs of choice are derived from grains, greens, tubers, nuts, and beans. The fourth is to eat less meat, as mentioned prior, and the fifth is to stick to just three beveragescoffee, that aforementioned wine (okay, yes), and lots and lots of water. Find out what the lastand least obviousgolden rule is here.

1. Keep a consistent sleep schedule

The Dalai Lama might not be a longevity expert per se, but he is doing pretty well at the spritely age of 85. One of his top six tips for extending your lifespan is to maintain a consistent sleep schedule. And even though he starts his day at 3 a.m., his 7 p.m. bedtime ensures he gets a solid eight hours of sleep per night.

Hobbies

1. Volunteer

One less-easy-to-imitate characteristic of those occupying the worlds Blue Zones is that they retain a sense of purpose throughout their lives. In America, we tend to put older people to pasture, so to speak, and they are less naturally integrated into family and community life, too.

One way to hack a sense of purpose in our (cold, heartless) societynot just when youre older but at any ageis to volunteer. Research shows that helping other people can actually help you to live a longer life. Our results show that volunteerism among older adults doesnt just strengthen communities, but enriches our own lives by strengthening our bonds to others, helping us feel a sense of purpose and well-being, and protecting us from feelings of loneliness, depression, and hopelessness, Eric S. Kim, PhD, research scientist at the Harvard T.H. Chan School of Public Health, said in a press release about the study. Find out more here, including how to adapt this hashtag-goals habit to pandemic times.

2. Grow a green thumb

According to Buettner, people in the Blue Zones, or longest-living areas of the world, garden well into their 90s and beyond. Gardening is the epitome of a Blue Zone activity because its sort of a nudge: You plant the seeds and youre going to be nudged in the next three to four months to water it, weed it, harvest it, he says. And when youre done, youre going to eat an organic vegetable, which you presumably like because you planted it. Find out more on the research behind this here.

3. Meditate

Not to state the obvious, but the Dalai Lamas longevity routine also includes regular meditation. And while he practices for seven hours a day, research shows that just five minutes per day can reap benefits such as sharpening your mind, reducing stress and, importantly, slowing aging.

4. Practice compassion

The Dalai Lama considers compassion to be one of the keys to happiness, and science says it has pro-social benefits, too. These might help us live longer lives, as humans thrive in the communities many Americans find it more difficult to build than those living in the Blue Zones do. Showing concern, care, and empathy to others can endear you to them and ensure that when the shoe is on the other foot, youve got others to lean on, too. This reciprocal relationship gives you that aforementioned sense of longevity-endowing purpose, too.

Go here to read the rest:
The 17 Best Longevity Tips Experts Taught Us in 2020 - Well+Good

Read More...

LifeBio Selected to Present at Innovator’s Pitch Challenge During the Inaugural Longevity, Health & Innovation Conference – PRNewswire

January 14th, 2021 11:56 am

MARYSVILLE, Ohio, Jan. 12, 2021 /PRNewswire/ --LifeBio, a leading age-tech solutions company using reminiscence methods and life story work for social engagement, announced today it has been selected to participate in the Innovator's Pitch Challenge (IPC) at the inaugural Longevity, Health & Innovationconference to be held virtually and concurrently during the 39th Annual J.P. Morgan Healthcare Week, January 11-15.

LifeBio's MyHello, a tech-powered, scalable live phone intervention to prevent loneliness in older adults and to address social determinants of health (SDoH), was one of only 37 early-stage company products among hundreds of entries invited to pitch to the life science and longevity investor judging panel. The two-day Innovator's Pitch Challenge includes a 4-minute pitch followed by live Q&A sessions on January 14-15. The purpose of the pitch is to advance technology in longevity and aging by connecting buyers, sellers, and investors.

"The COVID pandemic increased loneliness and isolation among older adults which we know leads to higher levels of depression, poorer cardiovascular and diabetes health and higher rates of Alzheimer's disease," said Beth Sanders, CEO and founder of LifeBio. "MyHello is designed to be a high-tech intervention for loneliness using existing landline or mobile phones and connecting older adults with engaging conversations with the power of life stories. Research shows we reduce depression and increase happiness and well-being using the LifeBio Reminiscence Method and personalized story methods."

Julianne Holt-Lunstadat Brigham Young University, one of the foremost researchers on social isolation and loneliness, found these conditions have as much impact on longevity as obesity or even smoking. It is estimated more than 42 million older adults feel isolated and lonely, whether they live alone or in congregate living communities. In 2020, isolation and loneliness for seniors were exacerbated by the safety restrictions during the pandemic. In addition to the individual impact, loneliness and social isolation also account for $6.7 billion in additional Medicare spending annually according to a 2017 reportby AARP.

LifeBio Solutions

LifeBio (www.LifeBio.com) has captured thousands of life stories, working with senior living, hospice, health insurance partners and other health providers. The company has been recognized for its innovative approach to creating solutions for social determinants of health in older populations with its MyHellosolutions http://www.MyHello.com, a focus of the new guidelines from the Centers for Medicare and Medicaid Services (CMS). LifeBio also recently received a $2.5 million grant from the National Institute on Aging (NIA) Small Business Innovative Research (SBIR) program to test an online platform using artificial intelligence (AI) to facilitate life story work for those with dementia and Alzheimer's. (Disclaimer: Federal Grant ID: R44AG069566the content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.)

LifeBio Inc., is a leading age-tech company with more than 20 years of experience creating social engagement solutions using scientifically-proven reminiscence and life story methods. Headquartered in Marysville, Ohio, LifeBio works with health care and senior living organizations to capture key memories and experiences for people age 65+ or those facing life-limiting conditions. Most of LifeBio's work has been with organizations serving older adults. However, LifeBio recognizes the need to increase support for mental health interventions across all age groups as part of its ever-evolving product portfolio and partnerships. Learn more at: http://www.LifeBio.comor http://www.MyHello.com.

To learn more about the Innovator's Pitch Challenge, hosted by Life Science Nation and Mary Furlong and Associates, register hereor go to: http://www.longevityhealthinnovation.com.

Media Contact: Beth Sanders LifeBio 614-580-0333 [emailprotected]

SOURCE LifeBio

Go here to read the rest:
LifeBio Selected to Present at Innovator's Pitch Challenge During the Inaugural Longevity, Health & Innovation Conference - PRNewswire

Read More...

Live longer: Chlorophyll reduces cancer risk and promotes liver health to boost longevity – Express

January 14th, 2021 11:56 am

Chlorophyll is a pigment present in all green plants and a few other organisms. It is required for photosynthesis, which is the process by which light energy is converted into chemical energy. According to health experts, chlorophyll should be part of our daily lives and with the numerous health benefits its easy to see why.

Chlorophyll contains vitamins, antioxidants, and therapeutic properties that all majorly benefit the body.

Dr Keith Kantor, nutritionist and dietician and CEO of the Nutritional Addiction Mitigation Eating and Drinking program said: Chlorophyllsuppresses appetite, aids in weight loss, decreases spikes in insulin which lessens cravings, helps with skin healing, helps in detoxifying the blood, reduces the risk for cancer, increases energy, helps in eliminating odours (as a natural deodorant), and helps in boosting the immune system.

People have used chlorophyll as a health supplement for many years.

A variety of medical studies have suggested that it may be helpful for skin conditions, body odours, and fighting certain kinds ofcancer.

READ MORE:How to live longer: Consume this spice to reduce heart disease risk and inhibit cancer

In a study published in the US National Library of Medicine National Institutes of Health, chlorophylls ability to extend lifespan was investigated..

Results of the study indicate that chlorophyll is absorbed by worms and is thus bioavailable, constituting an important prerequisite for antioxidant and longevity-promoting activities inside the body, noted the study.

It continued: Our study thereby supports the view that green vegetables may also be beneficial for humans.

In conclusion, our experiments demonstrate that chlorophyll exhibits substantial antioxidant activity and significantly improves antioxidant resistance ofC. elegans.

Therefore, dietary chlorophyll derivatives support the recommendation of nutritionists to eat green vegetables and salads containing high contents of chlorophyll, as this could also help to improve human health and prevent diseases.

In another study published in Science Alert, the effects of chlorophyll on body functioning and blood glucose levels were analysed.

The study noted: Blood glucose levels can be affected by the various types of chlorophyll.

Experiments have proven that chlorophyll has antioxidant activities that are present in various foods.

A diet rich in chlorophyll led to a slight decrease in the number of white blood cells, haematocrit, haemoglobin and an increase in red blood cells compared with control.

It is concluded that chlorophyll is likely to have important implications regarding blood sugar and has benefits in body weight with further studies being warranted.

In addition to its neuroprotective and appetite-suppressing effects, chlorophyll promotes liver health and balances the gut flora.

A recent study posted in Frontiers in Physiology in 2018 has found that chlorophyllin may help relieve hepatic fibrosis symptoms by reducing harmful gut bacteria.

The study also indicates that chlorophyllin may reduce liver inflammation and protect the small intestine in mice with hepatic fibrosis.

Its beneficial effects on the gut microbiota hold promise for future research.

Continue reading here:
Live longer: Chlorophyll reduces cancer risk and promotes liver health to boost longevity - Express

Read More...

Page 231«..1020..230231232233..240250..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick